
Second quarter 2023 results
Second quarter 2023 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Press releases
September 26, 2023
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
September 25, 2023
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
September 22, 2023
Press Release: Availability of the Q3 2023 Memorandum for modelling purposes
Contact our media team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
For any other request, please call the switchboard: +33 1 53 77 40 00
Publications
Half Year 2023 Financial Report
Half Year 2023 Financial Report XBRL Package
First quarter 2023 results
Fourth quarter and full year 2022 results
Email Alerts
Subscribe to our email alerts to receive our press releases.